Abivax SA (ABVX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Abivax SA (ABVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8115
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus infection. The company also develops various technology platforms including antiviral platform, immune enhancer platform and polyclonal antibody platform. Abivax is headquartered in Paris, France.

Abivax SA (ABVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Abivax SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
Licensing Agreements 13
ExpreS2ion Biotech Enters into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Equity Offering 16
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Debt Offering 18
Abivax to Raise up to USD23.4 Million in Private Placement of Bonds 18
Abivax SA – Key Competitors 19
Abivax SA – Key Employees 20
Abivax SA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Sep 28, 2018: Abivax first-half 2018 financial results and operations update 22
Mar 16, 2018: ABIVAX: 2017 Full-Year Results and Progress Report 24
Sep 20, 2017: ABIVAX First-Half 2017 Financial Results and Update 28
Mar 15, 2017: ABIVAX Announces 2016 Full-Year Results and Progress Report 31
Corporate Communications 34
Jun 25, 2018: Abivax Names Ian McGowan As Scientific Advisory Board Chair And Juergen Rockstroh As New Member 34
Jan 29, 2018: ABIVAX Names Carol L. Brosgart As Board Director 35
Oct 05, 2017: ABIVAX expands Scientific Advisory Board with appointment of renowned virologist and former President of the Pasteur Institute, Prof. Christian Brechot 36
Government and Public Interest 37
Jan 09, 2017: ABIVAX to receive €8.4 million from Bpifrance “Invest in the Future Program” (PIA) for the development of innovative antiviral drugs 37
Product News 38
10/12/2017: ABIVAX presents novel data on the efficacy of its immune enhancer ABX196 in animal model of liver cancer at the World Vaccine Congress 38
06/12/2017: ABIVAX to Receive €390,000 From Bpifrance for the Development of Its Ebola Hyperimmune Candidate 39
Feb 23, 2017: ABIVAX Has Discovered Novel Antiviral Molecules with Potential for Dengue Virus Treatment 40
Clinical Trials 41
Apr 04, 2017: ABIVAX initiates clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs in HIV Patients 41
Feb 02, 2017: Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Abivax SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Abivax SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Abivax SA, Deals By Therapy Area, 2012 to YTD 2018 9
Abivax SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Evotec and Abivax Enter into Partnership 11
ABIVAX Enters into Co-Marketing Agreement with Finlay Institute 12
ExpreS2ion Biotech Enters into Licensing Agreement with Abivax 13
Heber Biotec Enters Into Licensing Agreement with Abivax 14
ABIVAX Enters into Licensing Agreement with CIGB for ABX203 15
Abivax to Raise USD14 Million in Public Offering of Shares 16
Abivax Raises USD65 Million in IPO 17
Abivax to Raise up to USD23.4 Million in Private Placement of Bonds 18
Abivax SA, Key Competitors 19
Abivax SA, Key Employees 20
Abivax SA, Other Locations 21

List of Figures
Abivax SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abivax SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Abivax SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Abivax SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Abivax SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Abivax SA (ABVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Matisa Materiel Industriel S.A.:企業の戦略・SWOT・財務分析
    Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report Summary Matisa Materiel Industriel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Maharashtra State Power Generation Co Ltd-エネルギー分野:企業M&A・提携分析
    Summary Maharashtra State Power Generation Co., Ltd. (Mahagenco) is a state government-owned electricity company. The company generates and supplies electricity across the state of Maharashtra, India. Mahagenco owns and operates generation facilities, and uses diverse fuel sources such as thermal, g …
  • Swissgrid AG:企業の戦略的SWOT分析
    Swissgrid AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Dohler GmbH:企業の戦略・SWOT・財務分析
    Dohler GmbH - Strategy, SWOT and Corporate Finance Report Summary Dohler GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AmerisourceBergen Corp (ABC):医療機器:M&Aディール及び事業提携情報
    Summary AmerisourceBergen Corp (AmerisourceBergen) is a pharmaceutical sourcing and distribution services company. It offers a wide range of services ranging from drug distribution to manufacturer solutions including niche premium logistics services, reimbursement and pharmaceutical consulting servi …
  • Vygon SA:医療機器:M&Aディール及び事業提携情報
    Summary Vygon SA (Vygon) is a medical specialty company that designs, manufactures and markets single use medical and surgical products. The company offers products in various specialties such as paediatrics, neonatology, support for post-operative pain relief, anesthesia, emergency and intensive ca …
  • University of Michigan:企業のM&A・事業提携・投資動向
    University of Michigan - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's University of Michigan Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • ResApp Health Ltd (RAP):製薬・医療:M&Aディール及び事業提携情報
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Mattress Firm Holding Corp.:企業のM&A・事業提携・投資動向
    Mattress Firm Holding Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mattress Firm Holding Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • The Emirates Telecommunications Group:戦略・SWOT・企業財務分析
    The Emirates Telecommunications Group - Strategy, SWOT and Corporate Finance Report Summary The Emirates Telecommunications Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Halliburton Company:企業の戦略・SWOT・財務情報
    Halliburton Company - Strategy, SWOT and Corporate Finance Report Summary Halliburton Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Haworth, Inc.:企業の戦略・SWOT・財務分析
    Haworth, Inc. - Strategy, SWOT and Corporate Finance Report Summary Haworth, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pharmsynthez (LIFE):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmsynthez is a pharmaceutical company that manufactures and markets generic active pharmaceutical ingredients. The company offers production and sales of both officinal medicines (original OM) and active pharmaceutical ingredients (API). It offers drugs such as vazostenon, glaumax, cathal …
  • Gamma Medica Inc:医療機器:M&Aディール及び事業提携情報
    Summary Gamma Medica Inc (Gamma Medica), formerly Gamma Medica Ideas Inc is a medical device company that offers imaging solutions. The company designs, develops and manufactures imaging systems for clinical and pre-clinical applications. It offers lumagem, lumagem mbi workflow, lumagem procedure ov …
  • Energen Corporation:企業の戦略・SWOT・財務情報
    Energen Corporation - Strategy, SWOT and Corporate Finance Report Summary Energen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pilot Energy Ltd (PGY):石油・ガス:M&Aディール及び事業提携情報
    Summary Pilot Energy Ltd (Pilot), formerly Rampart Energy Ltd is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in Australia. Its projects include Australia EP416 and EP480, Australia WA-507-P, Australia WA-503-P and Aus …
  • Sojitz Corp (2768):企業の財務・戦略的SWOT分析
    Sojitz Corp (2768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • CaroGen Corp-製薬・医療分野:企業M&A・提携分析
    Summary CaroGen Corp (CaroGen) is a vaccine company that offers platform technology development services. The company develops and commercializes nanoparticle therapeutic vaccines. It utilizes its virus-like vesicle platform technology, a proprietary replication competent to develop nano particle th …
  • Medicines for Malaria Venture-製薬・医療分野:企業M&A・提携分析
    Summary Medicines for Malaria Venture (MMV) is a drug development and manufacturing company that discovers, develops and delivers anti malarial drugs. The company offers products that provide efficacy against drug-resistant strains of plasmodium falciparum, potential for intermittent treatments, saf …
  • Interprotein Corp-製薬・医療分野:企業M&A・提携分析
    Summary Interprotein Corp (Interprotein) is a drug discovery company that conducts research and develops small molecule drugs. The company provides IL-6 inhibitor, IgE inhibitor, notch1 inhibitor, tubulin polymerization inhibitors, TIM-3 inhibitor, NKG2A, HLA-E and CD94 inhibitor; KIR and HLA-C inhi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆